Clinical Trial

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with non-GCB DLBCL.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-14
Trial Details
NCT Number NCT07189065
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment 150 participants
Start Date 2025-11-27
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-16